Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3912]

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory...

Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA

$Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )$

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free...

Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )

Real world data supports ciltacabtagene autoleucel as effective option for...

Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...

Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared...

Dr Martin Kaiser - The Institute of Cancer Research, London UK

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London UK )

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted...

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail...

Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma. ( Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy )

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative...

Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients ( Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA )

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma ( Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA )

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Prof Brian Hill - Cleveland Clinic, Cleveland, USA

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )

Study indicates circulating tumour cell assessment should be part of multiple...

Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain

Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup ( Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain )

Initial treatment options for relapsed/refractory multiple myeloma patients

Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...

$Initial treatment options for relapsed/refractory multiple myeloma patients ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )$

More from ecancer